Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yushi Zhang

Showing results (11-20 of 235) with videos related to

Pageof 24
Sort By:
Asian Journal of Surgery|September 11, 2022
Adrenal perivascular epithelioid-cell tumor: A rare case reportZhangcheng Liao, Xiaoxue Chen, Yushi Zhang
Oncology Reports|January 1, 2016
Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor AYi Cai, Hanzhong Li, Yushi Zhang
European Urology|March 2, 2022
Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003Zhan Wang, Yang Zhao, Yushi Zhang
European Urology|December 26, 2021
Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145-8Zhan Wang, Yang Zhao, Yushi Zhang
Urology|January 10, 2017
ReplyYi Cai, Hanzhong Li, Yushi Zhang
Urology|January 10, 2017
Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland ChinaYi Cai, Hanzhong Li, Yushi Zhang
European Urology|October 23, 2016
Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85-90Yi Cai, Hanzhong Li, Yushi Zhang
Urology|October 30, 2016
Re: Kapoor et al.: Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML) (Urology 2016;89:19-26)Yi Cai, Hanzhong Li, Yushi Zhang
Asian Journal of Surgery|June 14, 2022
Papillary renal neoplasm with reverse polarity: A case reportXu Wang, Xinxin Mao, Yang Zhao, et al.
Oncology Letters|January 19, 2018
Clinical and genetic analysis of tuberous sclerosis complex-associated renal angiomyolipoma in Chinese pedigreesShuqiang Li, Yushi Zhang, Jinxing Wei, et al.
Pageof 24

Showing results (11-20 of 235) with videos related to

Sort By:
Pageof 24
Asian Journal of Surgery|September 11, 2022
Adrenal perivascular epithelioid-cell tumor: A rare case reportZhangcheng Liao, Xiaoxue Chen, Yushi Zhang
Oncology Reports|January 1, 2016
Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor AYi Cai, Hanzhong Li, Yushi Zhang
European Urology|March 2, 2022
Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003Zhan Wang, Yang Zhao, Yushi Zhang
European Urology|December 26, 2021
Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145-8Zhan Wang, Yang Zhao, Yushi Zhang
Urology|January 10, 2017
ReplyYi Cai, Hanzhong Li, Yushi Zhang
Urology|January 10, 2017
Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland ChinaYi Cai, Hanzhong Li, Yushi Zhang
European Urology|October 23, 2016
Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85-90Yi Cai, Hanzhong Li, Yushi Zhang
Urology|October 30, 2016
Re: Kapoor et al.: Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML) (Urology 2016;89:19-26)Yi Cai, Hanzhong Li, Yushi Zhang
Asian Journal of Surgery|June 14, 2022
Papillary renal neoplasm with reverse polarity: A case reportXu Wang, Xinxin Mao, Yang Zhao, et al.
Oncology Letters|January 19, 2018
Clinical and genetic analysis of tuberous sclerosis complex-associated renal angiomyolipoma in Chinese pedigreesShuqiang Li, Yushi Zhang, Jinxing Wei, et al.
Pageof 24